{"doi":"10.1186/s13023-024-03436-y","title":"The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition","abstract":"BACKGROUND: CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease is a newly identified condition with an estimated worldwide prevalence of < 100 patients. Patient interviews can ensure that what is important to patients is assessed in a clinical trial program. Due to the rare and potentially fatal nature of CHAPLE disease, interviews were conducted as part of the pozelimab clinical trial, rather than in a separate study before the trial. The aim of the interviews was to identify the key disease-related signs, symptoms, and health-related quality-of-life (HRQoL) impacts that are important and relevant to patients with CHAPLE disease. METHODS: Interviews were conducted with patients and/or caregivers at two timepoints (screening and Week 24) during the pozelimab trial to document the signs/symptoms and HRQoL impacts of CHAPLE disease, and document the most bothersome sign/symptom at screening. At Week 24, interviews gathered additional information on the patient experience from caregivers and patients (note: the impact of pozelimab treatment was also collected, though these results are presented elsewhere). RESULTS: Ten patients, aged 3-19 years, were enrolled in the trial; caregivers contributed to nine interviews. Thirty-one signs‌/symptoms and 65 HRQoL impacts were reported during the interviews. Abdominal pain, diarrhea, facial and peripheral edema/‌swelling, nausea, and vomiting emerged as the core signs/‌symptoms of CHAPLE disease (i.e., experienced by ≥ 90% of patients prior to treatment). The remaining 25 signs/symptoms were experienced by four or fewer (n ≤ 4, ≤ 40.0%) patients, and 15 were only reported by one patient each. Abdominal pain and facial edema were reported as the most bothersome signs/‌symptoms (n = 9, 90.0% and n = 1, 10.0%, respectively). The most frequently reported (i.e., ≥ 80% of interviews) HRQoL impacts were restricted diet (n = 10, 100.0%), sleep disruptions (n = 10, 100.0%), missing school (n = 9, 90.0%), ability to get dressed independently (n = 8, 80.0%), and difficulty engaging in play activities (n = 8, 80.0%). CONCLUSIONS: The main finding from these patient interviews is the identification of six core signs/symptoms of CHAPLE disease: abdominal pain, diarrhea, facial edema/swelling, peripheral edema/swelling, nausea, and vomiting. The severity of the core signs/symptoms leads to substantial impacts on patients' lives. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04209634. Registered 20 December 2019 https://classic. CLINICALTRIALS: gov/ct2/show/NCT04209634 .","journal":"Orphanet Journal of Rare Diseases","year":2025,"id":540331,"datarank":0.17872946188779695,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.013937618587580495,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.013937618587580495,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":2,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.964,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04209634"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":281900,"name":"Ahmet Özen","orcid":"0000-0001-8628-104X","position":1,"is_corresponding":false},{"id":1268401,"name":"Sarah Ollis","orcid":"0000-0002-1677-4081","position":2,"is_corresponding":false},{"id":241311,"name":"Hagit Baris Feldman","orcid":"0000-0003-4065-7560","position":3,"is_corresponding":false},{"id":1268402,"name":"Andrew Yaworsky","orcid":"0000-0003-3532-0795","position":4,"is_corresponding":false},{"id":1268403,"name":"Paolo Medrano","orcid":"0000-0002-0494-088X","position":5,"is_corresponding":false},{"id":1214740,"name":"Voranush Chongsrisawat","orcid":"0000-0002-6106-0504","position":6,"is_corresponding":false},{"id":1214742,"name":"Lorah Perlee","orcid":"0000-0001-6581-5540","position":7,"is_corresponding":false},{"id":1268875,"name":"Marisa Walker","orcid":null,"position":8,"is_corresponding":false},{"id":955501,"name":"Sharanya Pradeep","orcid":null,"position":9,"is_corresponding":false},{"id":1428130,"name":"Diane M. Turner‐Bowker","orcid":"0000-0002-8491-5704","position":10,"is_corresponding":false},{"id":585381,"name":"Alina Kurolap","orcid":"0000-0002-7005-3621","position":11,"is_corresponding":false},{"id":1215299,"name":"Orly Eshach Adiv","orcid":null,"position":12,"is_corresponding":false},{"id":103764,"name":"Michael J. Lenardo","orcid":"0000-0003-1584-468X","position":13,"is_corresponding":false},{"id":666201,"name":"Olivier Harari","orcid":"0000-0001-8214-489X","position":14,"is_corresponding":false},{"id":969344,"name":"Jessica J. Jalbert","orcid":"0000-0001-8566-6466","position":15,"is_corresponding":false},{"id":1268400,"name":"Leighann Litcher‐Kelly","orcid":"0000-0001-9005-6582","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":null,"created_at":"2026-07-19T02:52:38.861025Z","pmid":"39934837","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}